The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models

Neurological Research

Volumn 29, Issue 3, 2007, Pages 289-295

  Mi, Young Jeon ^a   Won, Yong Lee ^a   Ho, Young Kang ^a   Eun, Joo Chung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Dopamine agonists; Hemiparkinsonian rat models; L DOPA; Neuroprotection; Neurotoxicity

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BENSERAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; PRAMIPEXOLE; QUINPIROLE; TYROSINE 3 MONOOXYGENASE;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; FOREFOOT; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; STRIATONIGRAL DEGENERATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; LEVODOPA; MALE; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 34249033621     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313206X153996     Document Type: Article

References (56)

1. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998; 43: 551-554
2. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561-575
3. Basma AN, Morris EJ, Nicklas WJ, et al. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 1995; 64: 825-832
4. Lai CT, Yu PH. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 1997; 53: 363-372
5. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992; 7: 23-31
6. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501-510
7. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61: 1470-1478
8. Hefti F, Melamed E. Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry. Brain Res 1981; 225: 333-346
9. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984; 43: 990-993
10. Mytilineou C, Walker RH, JnoBaptiste R, et al. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003; 304: 792-800
11. Lyras L, Zeng BY, McKenzie G, et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigrostriatal pathway in normal cynomologus monkeys. J Neural Transm 2002; 109: 53-67
12. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508
13. Quinn N, Parkes D, Janota I, et al. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986; 1: 65-68
14. Camp DM, Loeffler DA, LeWitt PA. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 2000; 74: 1229-1240
15. Datla KP, Blunt SB, Dexter DT, et al. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001; 16: 424-434
16. Dziewczapolski G, Murer G, Agid Y, et al. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport 1997; 8: 975-979
17. Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742: 80-88
18. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-912
19. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996; 67: 2208-2211
20. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207-213
21. Yoshioka M, Tanaka K, Miyazaki I, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002; 43: 259-267
22. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994; 738: 222-229
23. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104: 209-228
24. Fornai F, Battaglia G, Gesi M, et al. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 2001; 898: 27-35
25. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838: 51-59
26. Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999; 64: 1275-1285
27. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661
28. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 (Suppl. 1): 23-30
29. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101
30. Przedborski S, Levivier M, Jiang H, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995; 67: 631-647
31. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493
32. Chang JW, Wachtel SR, Young D, et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience 1999; 88: 617-628
33. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998; 151: 334-342
34. Hudson JL, van Horne CG, Stromberg I, et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993; 626: 167-174
35. Kirik D, Georgievska B, Burger C, et al. Reversal of motor impairments in Parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 2002; 99: 4708-4713
36. Lee CS, Cenci MA, Schulzer M, et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000; 123: 1365-1379
37. Olsson M, Nikkhah G, Bentlage C, et al. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995; 15: 3863-3875
38. Lee WY, Kim GM, Lee JI. The behavioral changes and the patterns of dopamine neuronal degeneration after intrastriatal 6-hydroxydopamine injection in rat. J Korean Neurol Assoc 2000; 18: 741-747
39. Graham DG, Tiffany SM, Bell WR, Jr, et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644-653
40. Mena MA, Pardo B, Paino CL, et al. Levodopa toxicity in foetal rat midbrain neurones in culture: Modulation by ascorbic acid. Neuroreport 1993; 4: 438-440
41. Engber TM, Boldry RC, Kuo S, et al. Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992; 581: 261-268
42. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432
43. Maj J, Rogoz Z, Skuza G, et al. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1997; 324: 31-37
44. Lee EA, Lee WY, Kim YS, et al. The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Exp Neurol 2003; 184: 304-312
45. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994; 59: 401-415
46. Winkler C, Sauer H, Lee CS, et al. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1996; 16: 7206-7215
47. Rosner B. Fundamentals of Biostatics, 4th edn, Belmont, CA: Duxbury, 1995: pp. 314-315
48. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002; 58: S1-S8
49. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26: 428-435
50. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996; 93: 1956-1961
51. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8: 129-133
52. Kondo T. Levodopa therapy from the neuroprotection viewpoint from a clinical outlook. J Neurol 2005; 252 (Suppl. 4): IV32-IV36
53. Ferrario JE, Delfino MA, Stefano AV, et al. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res 2003; 47: 431-436
54. Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998; 54: 1046-1054
55. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44: 110-119
56. Takashima H, Tsujihata M, Kishikawa M, et al. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 1999; 159: 98-104